Literature DB >> 7997715

A unified method for monitoring and analysing controlled trials.

J Grossman1, M K Parmar, D J Spiegelhalter, L S Freedman.   

Abstract

Group sequential methods are becoming increasingly popular for monitoring and analysing large controlled trials, especially clinical trials. They not only allow trialists to monitor the data as it accumulates, but also reduce the expected sample size. Such methods are traditionally based on preserving the overall type I error by increasing the conservatism of the hypothesis tests performed at any single analysis. Using methods which are based on hypothesis testing in this way makes point estimation and the calculation of confidence intervals difficult and controversial. We describe a class of group sequential procedures based on a single parameter which reflects initial scepticism towards unexpectedly large effects. These procedures have good expected and maximum sample sizes, and lead to natural point and interval estimates of the treatment difference. Hypothesis tests, point estimates and interval estimates calculated using this procedure are consistent with each other, and tests and estimates made at the end of the trial are consistent with interim tests and estimates. This class of sequential tests can be considered in both a traditional group sequential manner or as a Bayesian solution to the problem.

Mesh:

Year:  1994        PMID: 7997715     DOI: 10.1002/sim.4780131804

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

Review 1.  Methods in health service research. An introduction to bayesian methods in health technology assessment.

Authors:  D J Spiegelhalter; J P Myles; D R Jones; K R Abrams
Journal:  BMJ       Date:  1999-08-21

2.  Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer.

Authors:  Rebecca A Miksad; Mithat Gönen; Thomas J Lynch; Thomas G Roberts
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

3.  A predictive probability design for phase II cancer clinical trials.

Authors:  J Jack Lee; Diane D Liu
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

Review 4.  Interim analysis: A rational approach of decision making in clinical trial.

Authors:  Amal Kumar; Bhaswat S Chakraborty
Journal:  J Adv Pharm Technol Res       Date:  2016 Oct-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.